Heart failure with preserved ejection fraction (HFpEF) currently represents the majority of all
heart failure cases in the community. Glucagon-like peptide-1 agonists represent a class of …

• The Semaglutide Treatment Effect in People with obesity and heart failure with preserved
ejection fraction (STEP-HFpEF) is a companysponsored, double-blind, placebo-controlled …

The glucagon-like peptide 1 receptor (GLP-1R) agonist semaglutide is effective for the
treatment of obesity and type 2 diabetes mellitus (T2DM). The purpose of this article is to …

Several clinical trials have shown that glucagon-like peptide-1 (GLP-1) receptor agonists
can lower the risk of major heart-related problems in individuals with type 2 diabetes …

Background Heart failure with preserved ejection fraction is increasing in prevalence and is
associated with a high symptom burden and functional impairment, especially in persons …

Over the past decade, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have
emerged as potent glucose lowering drugs for individuals with type 2 diabetes (T2DM). GLP …

Heart failure with preserved ejection fraction (HFpEF) has a high prevalence, affecting more
than 50% of patients with heart failure. HFpEF is associated with multiple comorbidities, and …

Background Semaglutide, a once‐weekly glucagon‐like peptide‐1 receptor agonist, has
shown promise in weight management and cardiovascular outcomes in other populations …

In patients with heart failure (HF) with preserved ejection fraction and obesity, treatment with
the glucagon-like peptide 1 receptor agonist semaglutide (2.4 mg) leads to large reductions …

Background More women than men have heart failure with preserved ejection fraction
(HFpEF). Objectives The purpose of this study was to assess baseline characteristics and …